You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 247 No. 2, January 8, 1982 TABLE OF CONTENTS
  JAMA
  •  Online Features
  CLINICAL CARDIOLOGY
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Advances in Antiarrhythmic Therapy

The Role of Newer Antiarrhythmic Drugs

Koonlawee Nademanee, MD; Bramah N. Singh, MD, PhD, FRCP

JAMA. 1982;247(2):217-222.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE APPROACH to the management of disorders of cardiac rhythm has undergone major changes in the last ten years.1,2 The early experience with surgery and with pacemakers suggests that these modes of therapy hold much promise; however, it is unlikely that they will have a major appeal for the largest numbers of patients needing antiarrhythmic therapy.1 Drug therapy is therefore likely to remain the mainstay of long-term antiarrhythmic treatment for both supraventricular as well as ventricular tachyarrhythmias.

Clinicians have long sought the "ideal" antiarrhythmic agent, one that has a wide spectrum of therapeutic efficacy, is potent, well tolerated by the patient while having little or no side effects, but with pharmacokinetics appropriate for long-term prophylaxis. Although the discovery of such a compound still appears elusive, many new drugs are now being evaluated in the United States.3,4 Their investigational use is growing, and some are likely to be approved . . . [Full Text PDF of this Article]


Author Affiliations

From the Department of Cardiology, Wadsworth Veterans Administration Medical Center, and the Department of Medicine, UCLA School of Medicine, Los Angeles.


Footnotes

This article is one of a series sponsored by the American Heart Association.

Reprint requests to the Cardiology Section (691/111E), Wadsworth Veterans Administration Medical Center, Wilshire and Sawtelle boulevards, Los Angeles, CA 90073 (Dr Singh).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.